MicroRNAs in Alzheimer's disease: function and potential applications as diagnostic biomarkers
W Wei, ZY Wang, LN Ma, TT Zhang, Y Cao… - Frontiers in molecular …, 2020 - frontiersin.org
Alzheimer's disease (AD) is the most common form of dementia. Although the incidence of
AD is high, the rates of diagnosis and treatment are relatively low. Moreover, effective means …
AD is high, the rates of diagnosis and treatment are relatively low. Moreover, effective means …
MicroRNA-298 reduces levels of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties
Alzheimer's disease (AD) is the most common age-related form of dementia, associated with
deposition of intracellular neuronal tangles consisting primarily of hyperphosphorylated …
deposition of intracellular neuronal tangles consisting primarily of hyperphosphorylated …
Internal ribosome entry site (IRES)-mediated translation and its potential for novel mRNA-based therapy development
R Marques, R Lacerda, L Romão - Biomedicines, 2022 - mdpi.com
Many conditions can benefit from RNA-based therapies, namely, those targeting internal
ribosome entry sites (IRESs) and their regulatory proteins, the IRES trans-acting factors …
ribosome entry sites (IRESs) and their regulatory proteins, the IRES trans-acting factors …
The amyloid precursor protein: A converging point in Alzheimer's disease
The decades of evidence that showcase the role of amyloid precursor protein (APP), and its
fragment amyloidβ (Aβ), in Alzheimer's disease (AD) pathogenesis are irrefutable. However …
fragment amyloidβ (Aβ), in Alzheimer's disease (AD) pathogenesis are irrefutable. However …
Potential implications of miRNAs in the pathogenesis, diagnosis, and therapeutics of Alzheimer's disease
L Wang, X Shui, Y Diao, D Chen, Y Zhou… - International Journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is a complex multifactorial disorder that poses a substantial
burden on patients, caregivers, and society. Considering the increased aging population …
burden on patients, caregivers, and society. Considering the increased aging population …
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's disease
Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic
treatment for mild-to-moderate Alzheimer's disease (AD). Amyloid-β peptide (Aβ) generated …
treatment for mild-to-moderate Alzheimer's disease (AD). Amyloid-β peptide (Aβ) generated …
Amyloid beta and microRNAs in Alzheimer's disease
N Amakiri, A Kubosumi, J Tran, PH Reddy - Frontiers in Neuroscience, 2019 - frontiersin.org
Alzheimer's disease (AD) is a progressive mental illness characterized by memory loss and
multiple cognitive impairments. In the last several decades, significant progress has been …
multiple cognitive impairments. In the last several decades, significant progress has been …
[HTML][HTML] LncRNA NEAT1 promotes Alzheimer's disease by down regulating micro-27a-3p
LX Dong, YY Zhang, HL Bao, Y Liu… - American journal of …, 2021 - ncbi.nlm.nih.gov
Objective: Alzheimer's disease (AD) is a common neurodegenerative disease. This study
was designed to investigate the roles of lncRNA NEAT1/miR-27a-3p axis in AD. Methods …
was designed to investigate the roles of lncRNA NEAT1/miR-27a-3p axis in AD. Methods …
[HTML][HTML] The role of synaptic microRNAs in Alzheimer's disease
Structurally and functionally active synapses are essential for neurotransmission and for
maintaining normal synaptic and cognitive functions. Researchers have found that synaptic …
maintaining normal synaptic and cognitive functions. Researchers have found that synaptic …
RNA dynamics in Alzheimer's disease
A Rybak-Wolf, M Plass - Molecules, 2021 - mdpi.com
Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder that
heavily burdens healthcare systems worldwide. There is a significant requirement to …
heavily burdens healthcare systems worldwide. There is a significant requirement to …